| Rhythm Pharmaceuticals Announces New Data Presentations on Patients with Acquired or Congenital Hypothalamic Obesity (N=35) Treated with Setmelanotide for up to Nine Months in French Early-access Program |
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32 nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the presentation of new, real-world data at two European congresses that show consistent improvements in body mass index (BMI), BMI-z, and hunger scores in a total of 35 patients with acquired or congenital hypothalamic obesity who were treated with setmelanotide for up to nine months. Physicians from Sorbonne University in Paris delivered two oral presentations with data from patients in the early-access programs in France. |
globenewswire.com |
2025-05-14 12:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript |
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript |
seekingalpha.com |
2025-05-07 19:21:23 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates |
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago. |
zacks.com |
2025-05-07 13:10:38 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update |
-- First quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences |
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences: Bank of America Securities 2025 Healthcare Conference on Wednesday, May 14, 2025 at 12:20 a.m. |
globenewswire.com |
2025-05-06 12:00:00 |
Czytaj oryginał (ang.) |
| Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know |
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-30 15:06:01 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last? |
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-25 14:40:47 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 |
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 7, 2025 to report its first quarter 2025 financial results and provide a corporate update. |
globenewswire.com |
2025-04-23 12:00:00 |
Czytaj oryginał (ang.) |
| Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder |
Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmelanotide to the U.S. and EU, for the treatment of patients with acquired hypothalamic obesity, expected in Q3 of 2025. Company pushing forward with oral MC4R-specific agonist to treat patients with acquired hypothalamic obesity known as bivamelagon; |
seekingalpha.com |
2025-04-08 17:38:07 |
Czytaj oryginał (ang.) |
| RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study |
Rhythm Pharmaceuticals stock gains 17% on meeting goals with statistical significance in the late-stage acquired hypothalamic obesity study for setmelanotide. |
zacks.com |
2025-04-08 16:25:32 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals (RYTM) Surges 17.1%: Is This an Indication of Further Gains? |
Rhythm Pharmaceuticals (RYTM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-04-08 12:10:36 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trial |
Rhythm Pharmaceuticals said on Monday that its experimental drug to treat a rare obesity disorder met the main goal in a late-stage trial. |
reuters.com |
2025-04-07 11:11:29 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic Obesity |
-- Patients with acquired hypothalamic obesity on setmelanotide therapy (n=81) achieved mean BMI change of -16.5% compared with +3.3% for placebo (n=39) at 52 weeks (p |
globenewswire.com |
2025-04-07 11:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic Obesity |
BOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Monday, April 7, 2025 at 8:00 a.m. ET to disclose topline results from the Pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity. |
globenewswire.com |
2025-04-06 16:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd. |
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it reacquired the rights to IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate its 2021 licensing agreement with RareStone Group Ltd. |
globenewswire.com |
2025-03-20 18:01:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan |
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced it has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity. |
globenewswire.com |
2025-03-19 18:01:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals and Raymond A. Wood Foundation Announce Research Collaboration |
New registry study to focus on impact of fatigue in people with craniopharyngioma New registry study to focus on impact of fatigue in people with craniopharyngioma |
globenewswire.com |
2025-03-18 09:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2024 Earnings Call Transcript |
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants David Connolly – Investor Relations and Corporate Communications David Meeker – Chairman, Chief Executive Officer and President Jennifer Lee – Executive Vice President, Head-North America Hunter Smith – Chief Financial Officer Yann Mazabraud – Executive Vice President, Head-International Conference Call Participants Derek Archila – Wells Fargo Seamus Fernandez – Guggenheim Securities Phil Nadeau – TD Cowen Whitney Ijem – Canaccord Genuity Tazeen Ahmad – Bank of America Joseph Stringer – Needham & Company Leland Gershell – Oppenheimer Anthea Li – Jefferies Ram Selvaraju – H.C. Wainwright & Company Jon Wolleben – Citizens JMP Operator Good day, and welcome to Rhythm Pharmaceuticals Fourth Quarter and Fiscal Year 2024 Earnings Conference Call. |
seekingalpha.com |
2025-02-26 15:46:44 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates |
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.70 per share a year ago. |
zacks.com |
2025-02-26 11:31:09 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update |
-- Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the second quarter of 2025 -- -- Completed enrollment in the Phase 2 trial of oral MC4R agonist bivamelagon in acquired hypothalamic obesity -- -- FDA approved expanded label for IMCIVREE to include children as young as 2 years old -- -- Raised approximately $75 million in gross proceeds under ATM equity offering program; Cash runway extended into 2027 -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-02-26 09:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven |
Rhythm Pharmaceuticals' 01/2025 presentation and Q4 2024 preliminary results press release highlight growing financial performance and promising pipeline developments. Investment thesis focuses on Rhythm's robust clinical progress and strategic positioning in the rare genetic obesity market. Rating justification is based on solid revenues, innovative product pipeline, and potential market expansion. |
seekingalpha.com |
2025-02-25 13:21:59 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on Wednesday, February 26, 2025 |
BOSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, February 26, 2025 to report its fourth quarter and full year 2024 financial results and provide a corporate update. |
globenewswire.com |
2025-02-13 10:00:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think Rhythm Pharmaceuticals (RYTM) Could Surge 26.36%: Read This Before Placing a Bet |
The consensus price target hints at a 26.4% upside potential for Rhythm Pharmaceuticals (RYTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-01-28 12:56:14 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals (RYTM) Soars 5.5%: Is Further Upside Left in the Stock? |
Rhythm Pharmaceuticals (RYTM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road. |
zacks.com |
2025-01-22 11:50:33 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones |
-- Preliminary unaudited net revenues from global sales of IMCIVREE ® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million for the full year of 2024 -- -- On track to report topline data from global Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity in the first half of 2025 -- |
globenewswire.com |
2025-01-10 09:15:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals' Obesity Treatments Target Less Crowded Space, Analyst Sees Long-Term Potential |
Oppenheimer initiated coverage on Rhythm Pharmaceuticals Inc. RYTM, a developer of treatment for rare obesity disorders. |
benzinga.com |
2024-12-20 16:24:12 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients as Young as 2 Years Old |
BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to include children as young as 2 years old. IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long-term in patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency. |
globenewswire.com |
2024-12-20 16:15:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old |
BOSTON, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) has expanded the marketing authorization for IMCIVREE® (setmelanotide) to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome (BBS) or genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or biallelic leptin receptor (LEPR) deficiency in adult and pediatric patients as young as 2 years old and older. |
globenewswire.com |
2024-12-03 08:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Five Presentations at ESPE 2024, including New Real-world Data in Pediatric Patients with Acquired or Congenital Hypothalamic Obesity Treated with Setmelanotide |
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to evaluate setmelanotide therapy in patients with congenital hypothalamic obesity -- |
globenewswire.com |
2024-11-18 09:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Study of Setmelanotide in Patients Between 2 and 5 Years Old in The Lancet Diabetes & Endocrinology |
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of results from its Phase 3 VENTURE trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in children between the ages of 2 and younger than 5 years old with Bardet Biedl syndrome (BBS) or pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The data are published in the peer-reviewed journal The Lancet Diabetes & Endocrinology . |
globenewswire.com |
2024-11-13 20:30:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces New Employment Inducement Grants |
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on November 7, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,750 shares of its common stock to three new employees. |
globenewswire.com |
2024-11-13 18:01:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences |
BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in fireside chats at two upcoming investor conferences: |
globenewswire.com |
2024-11-06 10:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2024 Earnings Call Transcript |
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM ) Q3 2024 Earnings Conference Call November 5, 2024 5:00 PM ET Company Participants David Connolly - Head of Investor Relations and Corporate Communications David Meeker - Chairman, President and Chief Executive Officer Jennifer Lee - Executive Vice President and Head of North America Yann Mazabraud - Executive Vice President and Head of International Hunter Smith - Chief Financial Officer Conference Call Participants Philip Nadeau - TD Cowen Corinne Johnson - Goldman Sachs Group, Inc. Seamus Fernandez - Guggenheim Securities Dae Gon Ha - Stifel, Nicolaus & Company, Inc. Whitney Ijem - Canaccord Genuity Corp. Jeff Hung - Morgan Stanley Tazeen Ahmad - Bank of America Merrill Lynch Joseph Stringer - Needham & Company Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by. |
seekingalpha.com |
2024-11-06 00:45:26 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates |
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.76 per share a year ago. |
zacks.com |
2024-11-05 20:10:22 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update |
-- Third quarter 2024 net revenue from global sales of IMCIVREE ® (setmelanotide) of $33.3 million -- -- Adult patients with acquired hypothalamic obesity (N=8) achieved mean BMI reduction of 12.8% on setmelanotide therapy at three months in French early-access program -- |
globenewswire.com |
2024-11-05 18:01:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 |
-- Real-world data showed mean BMI decrease of 12.8% in adult patients with acquired hypothalamic obesity (N=8) at three months on setmelanotide therapy; mean BMI decrease of 21.3% in patients (n=5) who reached six months -- -- Greater reduction in fat mass (29.7%) versus reduction in lean muscle mass (7.7%) reported from Phase 2 trial extension in patients with acquired hypothalamic obesity (n=11) after 12 months -- |
globenewswire.com |
2024-11-04 18:01:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release |
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-29 13:06:15 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome |
BOSTON and LONDON, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) and Axovia Therapeutics Ltd. today announced a joint research collaboration designed to advance the understanding of Bardet-Biedl syndrome (BBS). |
globenewswire.com |
2024-10-24 10:00:00 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces New Employment Inducement Grants |
BOSTON, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on October 4, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 30,050 shares of its common stock to nine new employees. |
globenewswire.com |
2024-10-08 20:01:00 |
Czytaj oryginał (ang.) |
| Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck |
IMCIVREE is FDA-approved for obesity due to genetic mutations and aims to expand its label to include children as young as 2 years old. The company is also exploring IMCIVREE for hypothalamic obesity in a phase 3 study, with data expected in the 1st half of 2025. Financially, Rhythm has $319.1 million in cash, but may need to raise more funds within the next 12 months. |
seekingalpha.com |
2024-09-22 11:36:38 |
Czytaj oryginał (ang.) |
| Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? |
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2024-09-18 15:50:22 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces New Employment Inducement Grants |
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on September 11, 2024, the Compensation & Management Development Committee of Rhythm's Board of Directors granted inducement restricted stock units, or RSUs, covering an aggregate of 15,450 shares of its common stock to four new employees. |
globenewswire.com |
2024-09-16 20:01:00 |
Czytaj oryginał (ang.) |
| Four Biotech Stocks Rally Toward Buy Points As Funds Load Up |
Biotech stocks have been rallying as funds load up. Five stocks have been outperforming the vast majority in the IBD database. |
investors.com |
2024-09-06 17:31:26 |
Czytaj oryginał (ang.) |
| Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids |
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old. |
zacks.com |
2024-08-27 15:35:23 |
Czytaj oryginał (ang.) |
| Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old |
-- Label expansion sought to treat younger children with Bardet-Biedl syndrome or POMC/LEPR deficiency -- -- FDA sets PDUFA goal date of December 26, 2024 -- |
globenewswire.com |
2024-08-26 12:02:00 |
Czytaj oryginał (ang.) |